Evidence map›Paper›PMID 28061803›Full record

ArticleBMC microbiology2017

Evaluation of MLVA for epidemiological typing and outbreak detection of ESBL-producing Escherichia coli in Sweden.

Lisa Helldal, Nahid Karami, Christina Welinder-Olsson, Edward R B Moore, Christina Åhren

Abstract read
In one paragraph

Article in BMC microbiology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
  3. Article
  4. Comparison of IncK-Antibiotics (Basel, Switzerland) · 2024
    Article
  5. Identity ofMicroorganisms · 2021
    Article
  6. Article
  7. Article
  8. Rapid and Simple UniversalApplied and environmental microbiology · 2019
    Article
  9. Article
  10. Article
  11. Genotypic characterization of gentamicin and cephalosporin resistantAntimicrobial resistance and infection control · 2017
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Lisa HelldalDepartment of Infectious Diseases, Institution of Biomedicine, Sahlgrenska Academy and Centre for Antibiotic Resistance Research (CARe) at the University of Gothenburg, Gothenburg, Sweden. lisa.helldal@vgregion.se.
Nahid KaramiDepartment of Infectious Diseases, Institution of Biomedicine, Sahlgrenska Academy and Centre for Antibiotic Resistance Research (CARe) at the University of Gothenburg, Gothenburg, Sweden.
Christina Welinder-OlssonDepartment of Infectious Diseases, Institution of Biomedicine, Sahlgrenska Academy and Centre for Antibiotic Resistance Research (CARe) at the University of Gothenburg, Gothenburg, Sweden.
Edward R B MooreDepartment of Infectious Diseases, Institution of Biomedicine, Sahlgrenska Academy and Centre for Antibiotic Resistance Research (CARe) at the University of Gothenburg, Gothenburg, Sweden.
Christina ÅhrenDepartment of Infectious Diseases, Institution of Biomedicine, Sahlgrenska Academy and Centre for Antibiotic Resistance Research (CARe) at the University of Gothenburg, Gothenburg, Sweden.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundTo identify the spread of nosocomial infections and halt outbreak development caused by Escherichia coli that carry multiple antibiotic resistance factors, such as extended-spectrum beta-lactamases (ESBLs) and carbapenemases, is becoming demanding challenges due to the rapid global increase and constant and increasing influx of these bacteria from the community to the hospital setting. Our aim was to assess a reliable and rapid typing protocol for ESBL-E. coli, with the primary focus to screen for possible clonal relatedness between isolates. All clinical ESBL-E. coli isolates, collected from hospitals (n = 63) and the community (n = 41), within a single geographical region over a 6 months period, were included, as well as clinical isolates from a polyclonal outbreak (ST131, n = 9, and ST1444, n = 3). The sporadic cases represented 36 STs, of which eight STs dominated i.e. ST131 (n = 33 isolates), ST648 (n = 10), ST38 (n = 9), ST12 and 69 (each n = 4), ST 167, 405 and 372 (each n = 3). The efficacy of multiple-locus variable number tandem repeat analysis (MLVA) was evaluated using three, seven or ten loci, in comparison with that of pulsed-field gel electrophoresis (PFGE) and multi locus sequence typing (MLST).

resultsMLVA detected 39, 55 and 60 distinct types, respectively, using three (GECM-3), seven (GECM-7) or ten (GECM-10) loci. For GECM-7 and -10, 26 STs included one type and eleven STs each included several types, the corresponding numbers for GECM-3 were 29 and 8. The highest numbers were seen for ST131 (7,7 and 8 types, respectively), ST38 (5,5,8) and ST648 (4,5,5). Good concordance was observed with PFGE and GECM-7 and -10, despite fewer types being identified with MLVA; 78 as compared to 55 and 60 types. The lower discriminatory power of MLVA was primarily seen within the O25b-ST131 lineage (n = 34) and its H30-Rx subclone (n = 21). Epidemiologically unrelated O25b-ST131 isolates were clustered with O25b-ST131 outbreak isolates by MLVA, whereas the ST1444 outbreak isolates were accurately distinguished from unrelated isolates.

conclusionMLVA, even when using only three loci, represents an easy initial typing tool for epidemiological screening of ESBL-E. coli. For the ST131-O25b linage, complementary methods may be needed to obtain sufficient resolution.

Indexed as

Disease OutbreaksMinisatellite RepeatsMolecular EpidemiologyBacterial Proteinsbeta-LactamasesCross InfectionDNA, BacterialDrug Resistance, BacterialElectrophoresis, Gel, Pulsed-FieldEscherichia coliEscherichia coli InfectionsGenes, BacterialGenetic LociGenotypeHospitalsHumansBacterial Proteinsbeta-LactamasescarbapenemaseDNA, BacterialEpidemiological typingESBLEscherichia coliH30-Rx ST131MLVAO25b-ST131

Identifiers

PMID28061803
PMCPMC5217547

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.